Deseret Laboratories Inc.

Drug Discovery Alliances is a provider of chemistry and formulation services bringing together scientific expertise and support during all stages of the R&D continuum for emerging biotechs, existing multinationals and the United States government. We provide a global service where our partners – located in N. America, China, Japan, Czech Republic, England, Germany and Italy – cover four key services:

Consulting
• CMC Project Management
• GMP Auditing
• Licensing
• Sourcing & Procurement

Drug Discovery
• Medicinal Chemistry

R&D/Pre-Clinical
• Analytical Method Development
• Catalysis Screening
• Crystallization
• Metabolites, Impurities ID & Synthesis
• Process Research
• Reference Standards
• Solid Form Capabilities

Manufacturing (Phase I-III)
• Advanced Intermediate Manufacturing
• API & Commercial Manufacturing
• cGMP Manufacturing
• Final Drug Product Manufacturing
• Formulation Development
• Quality and Regulatory Support
• Raw Material Manufacturing

Chemistry Technology Platforms
Aseptic Fill & Finish
• Chlorination
• Chromatography
• Cryogenic
• Distillation
• Fermentation
• Heck Reactions
• HPAPI / High Potency
• High Pressure
• High Temperature
• High Throughput / High Resolution X-ray Diffraction
• Hydrogenation
• Lyophilization
• Nitration
• Pastillation
• Phosgenation
• Polymorph Screening
• Powder Filling
• X-ray Crystallography

Project Examples
• 4 year program for development of Regulatory Starting Material supporting NDA filing for a neurology product
• Urgent API consulting for Clinical Phase III with supplier change and identified savings of $10M
• CMC project consulting on pre-IND candidates ($760M) for a CNS product licensed by Astellas
• Generic new formulation consulting supporting Clinical Phase III for 505(b)(2) for hypertension product
• Commercial API manufacture for ophthalmology product sourcing key suppliers leading to successful FDA approval
• Phase III API for antibody conjugate for oncology identifying key supplier

Integrated Drug Discovery and Development Services
Our integrated offering allows clients to access multiple outsourcing choices across the research and development value chain. We offer the following services

Analytical Services
Method Development & Validation
Extractables & Leachables
Syringability, Injectability, & Inhalation Study
Manufacturer Validation
Raw Material Qualification
ICH Stability & Release Testing
Impurity Analysis & Contaminant Identification
Pre-Clinical, Clinical, & Post-Approval


Pre-Formulation & Formulation

Formulation Optimization
Solid Stage Characterization
IND & NDA Submission Support
Counterfeit Analysis
Degradation Analysis
API Analysis
USP Monograph Testing
Dissolution Studies
Overcoming Solubility Issues
Toxicology Analysis
Clinical Trial Material Manufacturing
Excipient Base Identification
Bioequivalence Analysis
Disintegration Studies

Custom Synthesis
Process R&D

Chemistry R&D and Custom Synthesis
The HDH Pharma scientific team has earned its reputation through its problem solving skills and out of the box thinking when coping with challenging chemistry.
Reaction Optimization
Synthetic route development
Feasibility analysis of synthetic pathways
Methodology studies for process development
Exploratory studies for original compound synthesis

Custom Synthesis Services:
Impurities
Building Blocks
Reference Compounds
Reaction Intermediates
Pharmaceutical Reference Standards

Building blocks and screening compounds Including:
4, 5, 6, and 7– membered heterocycles, fused heterocycles
Lipids, Carbohydrates, and Nucleosides
Pyridines, Pyrimidines, Purines, Substituted Benzenes, Pyrazoles, Osoxazoles, Oxadiazoles, Indoles and Benzimidazoles
Aza-benzimidazoles, and Azitidine, Pyrrolidine, Piperidine

IRIX Pharmaceuticals, Inc. is a privately held company engaged in the generation of process technology for new and existing drugs.

IRIX offers the full capability of supplying API’s and complex pharma intermediates from pre-clinical stages, through all phases of clinical trials, registration/validation batches, launch and ongoing commercial quantities.

Formed to provide the Pharmaceutical Industry with a low-cost alternative for bringing new drugs to market rapidly, IRIX operates three sites for Process R&D and Clinical through Commercial cGMP production of API’s. Process R&D and early stage clinical supply for API’s is based in Florence, South Carolina. Late-stage clinical supply and commercial production is located in Greenville, South Carolina.

IRIX ensures compliance with all regulatory and quality requirements. Both the Greenville and Florence site were visited by the FDA in 2008 and 2009, respectively, with no 483s issued for either site.

IRIX supports new drug development in all functions necessary to bring a pharmaceutical candidate from discovery to market. IRIX provides seamless technology transfers both to/from Clients and internally for API syntheses.

The demonstrated expertise of the IRIX staff and the company’s emphasis on quality, economics, and timely delivery make it a choice CRMO (Contract Resources and Manufacturing Organization) for innovative pharmaceutical clients desiring to bring new drugs to the market rapidly.

Operating as an extension of the internal resources, IRIX offers sharp process solutions for an accelerated time to market at a very competitive cost.

AGC Chemicals Americas is a wholly owned subsidiary of AGC Inc., a $14 billion multinational corporation and one of the world’s largest manufacturers of glass, electronic displays and chemical products.

AGC Chemicals Americas, Inc. manufactures, markets and sells fluoroproducts including Fluon® fluoropolymer resins, Fluon+™ enhanced fluorinated materials and compounds, AFLAS® fluoroelastomers and AsahiKlin fluorinated solvents. The company also markets and sells specialty chemicals and materials including LUMIFLON® FEVE resins, AsahiGuard E-SERIES water and oil repellants, Fluon ETFE film, F-CLEAN® greenhouse films, Solesphere™ fine silica additives and various fluoro intermediates for pharma and agro products.

AGC Chemicals Americas was formed in 2004 through the merging of sister companies Asahi Glass Fluoropolymers USA and AGA Chemicals. Headquartered in Exton, Pa., including a state-of-the-art technology center, AGC Chemicals Americas maintains manufacturing operations in nearby Thorndale, Pa., a satellite sales office in Sao Paulo, Brazil and warehouses located throughout North America.

We are pleased to offer R&D services and technical support from our Business and Technical Center as part of our business development and technical solutions strategies.

Our mission can be summarized in the following phrase: "Your Dreams, Our Challenge."​ Working with others to combine knowledge and advanced technology, we create unique materials, solutions and reliable partnerships that help make ever greater achievements possible, and bring bolder ideas to life.

We invite you to further explore our web site to see how products from AGC Chemicals Americas can make a difference in your businesses.

A devision of ATTWILL Vascular Technologies, Attwill Medical Solutions purchased the assets of Anteco Pharma facility In 2017. Attwill Medical Solutions specializes in the lyophilization and related processing of pharmaceutical intermediates, medical devices and specialty food and nutritional ingredients.

ATTWILL operates a fully integrated commercialization business within a 36,500 square foot facility that includes R&D laboratories, piloting facilities and seven ISO 7 cleanrooms for manufacturing. Our ISO 13485 2016 manufacturing includes six freeze dryers that are used in the processing of ATTWILL products and in contract manufacturing of products that include pharmaceuticals, drug ingredients, medical devices, and nutraceuticals